What does “Skyrizi LOE date” mean?
“LOE” usually refers to the last date of “exclusivity” for a drug in the U.S., which can be tied to FDA marketing exclusivities (like patent/exclusivity protections) and is often used when forecasting when competitors can enter with biosimilars or generics. The exact “LOE date” depends on which exclusivity and which product (biosimilar) you mean.
What is Skyrizi (risankizumab-rzaa) and when could exclusivity end?
Skyrizi is a biologic (risankizumab-rzaa). For biologics, the relevant “entry” question often becomes: when can biosimilars launch (subject to patent and exclusivity status), which is why many analysts look up an LOE/expiry timeline for Skyrizi.
Where can I check the latest Skyrizi LOE / exclusivity date?
DrugPatentWatch tracks drug patent and exclusivity information and is commonly used to look up LOE dates for branded products. You can check Skyrizi’s current forecast there:
- DrugPatentWatch – Skyrizi (risankizumab): https://www.drugpatentwatch.com/ (search for “Skyrizi” on the site)
Why LOE dates can differ depending on the biosimilar or regulator entry scenario
Even when an “exclusivity” date is known, biosimilar launches can still be delayed by:
- Patents that expire later than exclusivity, or that are still in force.
- Patent litigation (automatic stays and other statutory mechanisms).
- The specific FDA exclusivity type being cited.
If you tell me whether you mean “FDA biosimilar entry LOE” or “patent/market exclusivity LOE,” I can narrow what you should be looking for on the LOE timeline.
Quick clarification so I can give the exact date you want
Do you want the LOE date for:
1) U.S. marketing exclusivity (biosimilar launch forecasting), or
2) a specific biosimilar candidate, or
3) a specific indication (Skyrizi has multiple FDA-approved uses)?
Reply with the one you mean, and (if you have it) the LOE format you’re using (e.g., “LOE1/LOE2” or “first potential launch”).
Sources
- https://www.drugpatentwatch.com/